In this exclusive MedPage Today video, Specht is joined via Zoom by study co-lead, Heather Jacene, MD, of Brigham and Women's Hospital and Dana-Farber Cancer Institute in Boston, to explain how ...

BERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for patients with bone metastases from breast cancer, and also appeared to be ...

A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an improved method for predicting treatment benefits in patients with hormone ...

If a cancer patient has bone metastases, they will frequently have anemia as well. Given that the bone marrow is the site of blood cell formation, this observation is perhaps not unexpected. But its ...

Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis.

Stage 4 RCC is metastatic, with common spread to lungs, bones, liver, brain, and adrenal glands. Understanding IMDC risk is ...